EA201991337A1 - Средство для лечения деменции различной этиологии - Google Patents

Средство для лечения деменции различной этиологии

Info

Publication number
EA201991337A1
EA201991337A1 EA201991337A EA201991337A EA201991337A1 EA 201991337 A1 EA201991337 A1 EA 201991337A1 EA 201991337 A EA201991337 A EA 201991337A EA 201991337 A EA201991337 A EA 201991337A EA 201991337 A1 EA201991337 A1 EA 201991337A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dementia
treatment
ethyl
relates
various
Prior art date
Application number
EA201991337A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991337A1 publication Critical patent/EA201991337A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к медицине, конкретно к фармакологии, и касается новой липосомальной композиции на основе метил-4-[2-оксо-1,2-бис-[[2-(4-пиридинил)этил]амино]этил]бензоат сукцината в качестве средства с направленной доставкой для лечения деменции различной этиологии. Заявленную композицию получают пленочным способом с последующей гидратацией и обработкой ультразвуком.
EA201991337A 2016-11-28 2017-11-28 Средство для лечения деменции различной этиологии EA201991337A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016146594A RU2016146594A (ru) 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии
PCT/RU2017/050122 WO2018097768A1 (ru) 2016-11-28 2017-11-28 Средство для лечения деменции различной этиологии

Publications (1)

Publication Number Publication Date
EA201991337A1 true EA201991337A1 (ru) 2019-11-29

Family

ID=62196182

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991337A EA201991337A1 (ru) 2016-11-28 2017-11-28 Средство для лечения деменции различной этиологии

Country Status (4)

Country Link
US (1) US20200281908A1 (ru)
EA (1) EA201991337A1 (ru)
RU (1) RU2016146594A (ru)
WO (1) WO2018097768A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3990028A4 (en) * 2019-06-26 2023-08-09 Biorchestra Co., Ltd. MICELLAR NANOPARTICLES AND ASSOCIATED USES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080012825A (ko) * 2005-01-21 2008-02-12 인트로겐 테라페티스, 인코퍼레이티드 표적 세포가 치료적 및 예방적 핵산에 지속 노출되게 하는국소 투여
RU2457205C2 (ru) * 2010-09-07 2012-07-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" Способ, соединение и фармацевтическая композиция и лекарственное средство для восстановления утраченной памяти в норме и патологии

Also Published As

Publication number Publication date
WO2018097768A1 (ru) 2018-05-31
RU2016146594A (ru) 2018-05-28
RU2016146594A3 (ru) 2020-02-06
US20200281908A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MY179802A (en) Hydrochloride salt form for ezh2 inhibition
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20160609A1 (es) Piperidil-etil-pirimidina sustituido como inhibidor de grelina o-acil transferasa
MX347692B (es) Inhibidores del virus de la hepatitis c.
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
BR112015022856A8 (pt) inibidores de protease de cetona de epóxi de tripeptídeo e dipeptídeo
BR112019003320A2 (pt) compostos de heteroaril carboxamida como inibidores de ripk2
MX2019007629A (es) Proceso para la preparacion de un derivado de 2-piridiletilcarboxamida.
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
EA201892264A1 (ru) Производные тетрагидроизохинолина
EA201591684A1 (ru) Кристаллические формы ингибиторов тирозинкиназы и их солей
EA201692300A1 (ru) Производные карбоксамида
EA201791346A1 (ru) ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
EA201892539A1 (ru) Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
EA201991337A1 (ru) Средство для лечения деменции различной этиологии